NDAORALTABLET
Approved
Sep 2025
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
6
Data completeness
6/8 — Strong
INLURIYO (imlunestrant) by Eli Lilly and Company is estrogen receptor antagonists [moa]. Approved for estrogen receptor antagonist [epc]. First approved in 2025.
Drug data last refreshed 22h ago
Mechanism of Action
Estrogen Receptor Antagonists
Pharmacologic Class:
Estrogen Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (6)
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Started May 2026
600 enrolled
Breast Neoplasms
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
Started Oct 2022
8,000 enrolled
Breast Neoplasms
A Study of Imlunestrant (LY3484356) in Healthy Women
Started Sep 2022
20 enrolled
Healthy
A Study of Imlunestrant (LY3484356) in Female Healthy Participants
Started Jul 2022
113 enrolled
Healthy
A Study of Imlunestrant (LY3484356) in Female Participants With Impaired Liver Function
Started Jul 2022
27 enrolled
Hepatic InsufficiencyHealthy
Worked on INLURIYO at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.